Correction EQL Pharma signs a license agreement with a large pharmaceutical company in Türkiye for Mellozzan (melatonin)

Previous press release is corrected due to a misstatement about local requirements in Türkiye.

EQL has entered into an exclusive license agreement with a large pharmaceutical company for its product Mellozzan (melatonin) for Türkiye and Kazakhstan. "EQL has previously signed license agreements with parties for a number of countries, but this is a milestone as it is our first agreement with the sale of one of our products outside the borders of Europe," says Axel Schörling, CEO at EQL Pharma.

Mellozzan contains the sleep hormone melatonin and is indicated for children who have ADHD and suffer from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan will probably be the first melatonin product in Türkiye and Kazakhstan with that paediatric indication. The drug is also indicated for the short-term treatment of jet lag in adults.

"We are of course extremely happy about this agreement", says Axel Schörling. "These are two countries with a total of over 105 million inhabitants, and our license taker’s size and reach mean that a great many children and their caretakers will have the opportunity for a good night's sleep, which has a huge impact on quality of life and schooling".

The agreement includes a so-called tech transfer to produce Mellozzan locally to provide an easier and earlier access to patients.

The agreement also includes a small license fee and a single-digit royalty on all sales.

EQL Pharma has ongoing negotiations for more license agreements on Mellozzan with other players in and outside of Europe.

For more information contact:

Axel Schörling,

CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling niche pharmaceuticals. The company currently has more than 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets and a couple of originals. In addition to these, there is a significant pipeline of mainly niche generics for launch in 2023 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.